Iran is one of the world’s major producers of oil, though sanctions by Western countries have limited its sales. If a wider war erupts, it could slow the flow of Iran’s oil to its customers and keep the price of…
The acquisition was completed on a cash-free, debt-free basis, with an upfront consideration of ₹400 crore and a potential additional payout of up to ₹72.5 crore over the next 24 months, subject to agreed conditions. Shares of ITC Ltd ended…
NTPC to raise ₹4,000 crore through non-convertible debentures (NCDs) on June 17, 2025, to fund capital expenditure, loan refinancing, and other corporate needs. Meanwhile, the third unit (660 MW) of the North Karanpura Super Thermal Power Project has commenced commercial…
Rekha Jhunjhunwala has brought her stake in Nazara Technologies down to zero, selling shares worth ₹334 crore on June 13 as the gaming stock surged to a near four-year high.
The financial results will be formally presented to the board on July 23 for final approval. Shares of Infosys Ltd ended at ₹1601.55, down by ₹5.85, or 0.36%, on the BSE.
The facility can continue selling approved drugs and will also receive approvals for new filings. Shares of Syngene International Ltd ended at ₹652.45, down by ₹10.45, or 1.58%, on the BSE.
Within Indian equities, small-cap stocks outperformed across all timeframes, delivering 21% returns over the past three months, 39% from the market bottom in March 2020, and 36% over five years. Mid-caps followed, while large-caps lagged, the fund house said.
Zydus and Lupin launched the generic version of Myrbetriq at risk in April 2025.
In the week ended June 13, the FIIs offloaded ₹1,246 crore amount of equities, while domestic institutional investors (DIIs) continued their buying streak with net purchases totaling ₹18,637 crore, exchange data showed.
Ganorkar has been heading the India business of Sun Pharma since 2019 and will take over as MD effective September 1, 2025. Shares of Sun Pharmaceutical Industries Ltd ended at ₹1688.70, up by ₹1.70, or 0.10%, on the BSE.